Among patients with CRC, the proportion with HER2 IHC 3 + tumors was higher in those who were KRAS/NRAS wild type positive (10/167) compared to those who were positive for KRAS or NRAS mutants (3/156), although the prevalence of HER2 IHC 3 + in these populations was low (Fig. 5). Here, NRAS is linked to colorectal carcinoma.